FiercePharma· @FiercePharma · X·· 9 天前精选AI 评分75
AI 导读
礼来旗下 Inluriyo 与 CDK4/6 抑制剂 Verzenio 的组合疗法获 FDA 批准。Fierce Pharma 称，此举强化了礼来在竞争激烈的口服 SERD 领域的地位。
推荐理由
礼来口服 SERD 与 CDK4/6 抑制剂组合获 FDA 批准，可观察其在拥挤的口服 SERD 赛道中的竞争位置。
正文
Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its Inluriyo with its CDK4/6 inhibitor Verzenio. https://www.fiercepharma.com/pharma/eli-lilly-escalates-oral-serd-battle-fda-approval-inluriyo-verzenio-combo $LLY
来源：FiercePharma · x.com